Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • PMN310 | Amyloid-Beta
    • PMN267 | TDP-43
    • PMN442 | Alpha-Synuclein
    • Vaccines
    • Posters & Publications
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Jun 3, 2021

ProMIS Neurosciences Files Preliminary Short Form Base Shelf Prospectus

May 27, 2021

ProMIS Neurosciences appoints renowned scientist, Dr. David Wishart as Chief Physics Officer

May 25, 2021

ProMIS Neurosciences initiates commercialization of COVID-19 serology assay

May 21, 2021

ProMIS Neurosciences re-initiates path to IND for PMN310 with producer cell line development

May 19, 2021

ProMIS Neurosciences appoints accomplished biotechnology executive, Neil Warma, to its Board of Directors

May 14, 2021

ProMIS Neurosciences Announces First Quarter 2021 Results

May 12, 2021

ProMIS Neurosciences appoints renowned neuroscientist, Dr. Rudolph Tanzi, as Chair of Scientific Advisory Board

Mar 31, 2021

ProMIS Neurosciences Announces Fiscal Year 2020 Results

Mar 22, 2021

ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors

Feb 2, 2021

ProMIS Neurosciences Offers Perspectives on Recent Progress in the Alzheimer’s/Amyloid Field

  • arrow_back
  • 1…
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • …25
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2025 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy